A patient is reported who presented with severe polymyositis and pulmonary collapse with infection. Investigations failed to confirm an underlying bronchial carcinoma but post-mortem examination revealed unsuspected Hodgkin's disease. The authors wish to draw attention to the rare but important association between polymyositis and treatable lymphomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426130 | PMC |
| http://dx.doi.org/10.1136/pgmj.57.670.526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Aim Of The Work: The aim of our work was to describe the current epidemiological situation of Hodgkin's lymphoma (HL) with a possible global prediction for the year 2040.
Methods: We obtained data on incidence and mortality of HL using the GLOBOCAN database. The rating was done specifically for men and women and together, with an age range of 0-85+ years.
Beyond The Basics: Unveiling Superior Vena Cava Compression in Hodgkin's Lymphoma.
Cureus
November 2024
Internal Medicine/Pulmonary Critical Care, Appalachian Regional Healthcare, Harlan, USA.
Hodgkin's lymphoma (HL) is a malignancy of the lymphocytes in the lymph nodes and presents with non-specific systemic symptoms like fever, night sweats, and weight loss. While HL often involves the mediastinum, it rarely causes superior vena cava (SVC) syndrome, and eosinophilia is noted in approximately 15% of cases. Here, we report a unique presentation of HL in a 52-year-old male with a history of chronic pruritus, chronic kidney disease, and inactive hepatitis B.
View Article and Find Full Text PDFUnusual Presentation of a Pediatric Burkitt's Lymphoma With Infiltration of the Interatrial Septum.
J Pediatr Hematol Oncol
December 2024
Division of Paediatric Cardiology.
Background: Burkitt's lymphoma (BL) is the most common subtype of non-Hodgkin lymphoma in children, typically presenting with extranodal masses in areas such as the abdomen, face, and neck. Cardiac involvement in BL is extremely rare, especially in pediatric patients, and has significant implications for diagnosis, management, and prognosis.
Case Presentation: A 6-year-old male patient with Burkitt's lymphoma, presenting with an uncommon infiltration of the interatrial septum, is described.
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
Am J Hematol
December 2024
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment of aggressive large B-cell lymphoma (aLBCL). Patients with transformed indolent non-Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR for this distinct, historically high-risk group are poorly understood. We conducted a multicenter retrospective study of 1182 patients with aLBCL receiving standard-of-care CAR T between 2017 and 2022, including 338 (29%) with tiNHL.
View Article and Find Full Text PDFPopulation Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
Clin Pharmacokinet
December 2024
Clinical Pharmacology and Quantitative Science, Genmab, Plainsboro, NJ, USA.
Background And Objectives: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL.
Methods: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!